Oxford Biodynamics plc develops and commercializes precision medicine tests based on its proprietary EpiSwitch® 3D gene regulation technology. The company offers a range of molecular diagnostic tests, including the EpiSwitch® Prostate Screening Test and the EpiSwitch® Checkpoint Inhibitor Response Test, which assist healthcare providers in making informed treatment decisions. Oxford Biodynamics collaborates with pharmaceutical, biotech, and academic institutions for clinical development and biomarker discovery, operating primarily in the UK and the US, with additional facilities in Malaysia. The company also plans to launch the EpiSwitch® Orion cloud platform to enhance genomic data analysis and accessibility.